Principal Investigator: Bonnie I. Glanz, PhD
Background: Shared decision-making (SDM) is a model of medical decision-making distinguished by an emphasis on patient knowledge, flow of information between patient and physician, and a shared responsibility among physician and patient regarding final treatment decisions. This may be particularly well-suited for chronic conditions such as multiple sclerosis (MS). We examined SDM in individuals with MS treated at the Brigham MS Center.
Methods: 161 patients completed an anonymous survey that included a standard measure of SDM (SDM-Q-9) as well as questions to assess disease characteristics, risk attitudes and disease expectations. Summary statistics for each question were calculated, and subjects on high efficacy versus traditional efficacy treatments were compared.
Results: Patients reported a high level of SDM in their most recent treatment decisions as well as overall satisfaction with their treatment choices. Although there was no difference between treatment groups in terms of SDM, patients taking high efficacy treatments had significantly higher risk propensity scores and higher disease worsening expectations than patients on traditional efficacy treatments.
Discussion: Our study demonstrated both the high occurrence of SDM among patients at the Brigham MS Center as well as high overall satisfaction with treatment decisions.
Background: Shared decision-making (SDM) is a model of medical decision-making distinguished by an emphasis on patient knowledge, flow of information between patient and physician, and a shared responsibility among physician and patient regarding final treatment decisions. This may be particularly well-suited for chronic conditions such as multiple sclerosis (MS). We examined SDM in individuals with MS treated at the Brigham MS Center.
Methods: 161 patients completed an anonymous survey that included a standard measure of SDM (SDM-Q-9) as well as questions to assess disease characteristics, risk propensity and disease expectations. Summary statistics for each question were calculated, and subjects on high efficacy versus traditional efficacy treatments were compared.
Results: Patients reported a high level of SDM in their most recent treatment decisions as well as overall satisfaction with their treatment choices. Although there was no difference between treatment groups in terms of SDM, patients taking high efficacy treatments had significantly higher risk propensity scores and higher likelihood of disease worsening scores than patients on traditional efficacy treatments.
Discussion: Our study demonstrated both the high occurrence of SDM among patients at the Brigham MS Center as well as high overall satisfaction with treatment decisions.
If the PDF viewer does not load initially, please try refreshing the page.
